Abstract 93P
Background
In the global, randomized, double-blind, phase 3 FRESCO-2 study (NCT04322539), treatment with F + BSC significantly improved overall survival (OS) and progression-free survival (PFS) vs P + BSC, with a favorable toxicity profile in patients (pts) with refractory mCRC. Here we report efficacy and safety data according to race for Asian and non-Asian patient subgroups.
Methods
Patients in USA, Europe, Japan, and Australia were randomized 2:1 to receive F (5 mg) or matching P, PO QD, for 21 days every 28 days + BSC. Eligible pts had received prior chemotherapy, anti-VEGF therapy and, if RAS wild type, anti-EGFR therapy; if BRAFV600E mutant or MSI-H, an appropriate targeted regimen; and prior trifluridine/tipiracil and/or regorafenib. Primary endpoint was OS.
Results
Overall, 61 Asian pts (6 in USA, 55 in Japan) and 594 non-Asian pts were enrolled. Asian vs non-Asian pts were younger (64 vs 52% aged <65 years), had a higher proportion of ECOG PS of 0 (59 vs 41%), and a higher proportion had received >3 lines of prior therapy for metastatic disease (80 vs 71%); pt characteristics were generally balanced between treatment arms within subgroups. OS was improved with F + BSC vs P + BSC in Asian (median 7.1 vs 4.7 months; HR 0.38, 95% CI 0.17–0.83) and non-Asian pts (median 7.6 vs 4.8 months; HR 0.70, 95% CI 0.57–0.86). PFS was also improved with F + BSC vs P + BSC in both Asian and non-Asian pts (Table). The incidence of TEAEs with F + BSC vs P + BSC was 98 vs 84% in Asian pts and 99 vs 94% in non-Asian pts. Grade ≥3 TEAEs are shown in the table. Table: 93P
FRESCO-2 efficacy and safety data overall and by Asian and non-Asian race subgroups
ITT population | F + BSC n=461 | P + BSC n=230 | ||
Median OS, months HR (95%CI) | 7.4 | 4.8 | ||
0.66 (0.55–0.80); p<.001 | ||||
Median PFS, months HR (95%CI) | 3.7 | 1.8 | ||
0.32 (0.27–0.39); p<.001 | ||||
Asian pts | Non-Asian pts | |||
F + BSC n=43 | P + BSC n=18 | F + BSC n=390 | P + BSC n=204 | |
Median OS, months HR (95%CI) | 7.1 | 4.7 | 7.6 | 4.8 |
0.38 (0.17–0.83) | 0.70 (0.57–0.86) | |||
Median PFS, months HR (95%CI) | 3.6 | 1.7 | 3.7 | 1.9 |
0.29 (0.14–0.58) | 0.32 (0.26–0.39) | |||
Safety population | Asian pts* | Non-Asian pts | ||
F + BSC n=42 | P + BSC n=19 | F + BSC n=387 | P + BSC n=202 | |
Grade ≥3 TEAEs, % | 69% | 32% | 61% | 51% |
*One patient assigned to fruquintinib arm received placebo instead.
Conclusions
There was a clinically meaningful improvement in OS and PFS with F + BSC vs P + BSC in both Asian and non-Asian pts. Despite similar median OS between groups, the HR was different in the Asian subgroup; more results from sensitivity analyses may be reported. The safety and efficacy subgroup analysis results were consistent with the overall FRESCO-2 population and with the established monotherapy profile of F.
Clinical trial identification
NCT04322539.
Editorial acknowledgement
Medical writing support, under the direction of the authors, was provided by Helen Wilkinson, PhD of Ashfield MedComms, an Inizio Company, funded by Takeda Pharmaceuticals, U.S.A., Inc., Lexington, MA.
Legal entity responsible for the study
HUTCHMED.
Funding
HUTCHMED.
Disclosure
D. Kotani: Financial Interests, Personal, Other, Honoraria: Takeda, Chugai, Lilly, MSD, Ono, Taiho, Bristol Myers Squibb, Daiichi Sankyo, Pfizer, Eisai, Merckbiopharma, Sysmex, Seagen, Novartis; Financial Interests, Personal, Research Funding: Ono, MSD, Novartis, Servier, Janssen, IQVIA, Syneoshealth, Cimic, Cimicshiftzero. T. Yoshino: Financial Interests, Personal, Other, Honoraria: Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd, MSD K.K., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd ; Financial Interests, Personal, Research Funding: Amgen K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., FALCO biosystems Ltd., Genomedia Inc., Molecular Health GmbH, MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Roche Diagnostics K.K., Sanofi K.K., Sysmex Corp., Taiho Pharmaceutical Co., Ltd.; Financial Interests, Personal, Speaker, Consultant, Advisor, Consulting fees: Sumitomo Corp. A.S. Paulson: Financial Interests, Institutional, Research Grant, Receiving grants or contracts for clinical trials: Ipsen, Bristol Myers Squibb, Exelixis, HUTCHMED, Taiho, Lilly, AstraZeneca, Incyte, Deciphers, G1 Therapeutics, Zentalkis, Tempus, Camurus, Relay Therapeutics, Nucana, Merck, Bayer, Sotio, Innovations Cellular Therapeutics; Financial Interests, Personal, Other, Educational event fees: Ideo Oncology, MJH Life Sciences; Financial Interests, Personal, Other, Travel support: Pfizer; Financial Interests, Personal, Advisory Board, Participation on a data safety monitoring or advisory board: Amgen, Bristol Myers Squibb, Eisai, Ipsen, AAA, Exelixis, Pfizer, QED, Lilly, Mirati, HUTCHMED, Astellas, Incyte, AADi, Stromatis, EMD, Serono; Financial Interests, Personal, Stocks/Shares: Aptose, Actinium, Alexion; Financial Interests, Personal, Other, Payment for medical writing services: Bayer, Ipsen, HUTCHMED, Exelixis. T. Masuishi: Financial Interests, Institutional, Research Grant, Grants or contracts: MSD, Daiichi Sankyo, Ono, Novartis, Amgen, Syneos Health Clinical, Boehringer Ingelheim, Pfizer, Cimic Shift Zero, Eli Lilly; Financial Interests, Personal, Other, Payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events: Takeda, Chugai, Merck Bio Pharma, Taiho, Bayer, Lilly Japan, Yakult Honsha, Sanofi, Daiichi Sankyo, Ono, Bristol Myers Squibb. H. Hochster: Financial Interests, Personal, Speaker, Consultant, Advisor: Merck, Processa, TRIGR; Financial Interests, Personal, Invited Speaker: Natera; Financial Interests, Personal, Other, data safety monitoring or advisory board: Seattle Genetics, Genentech. J. Krauss: Financial Interests, Institutional, Research Grant, Grants or contracts to their institution: Genentech, Bristol Myers Squibb, Amgen, Isofol Medical, Novartis, Tempest Therapeutics, MedImmune/AstraZeneca, AbbVie, MedImmune, Icon, Turning Point Therapeutics. Y. Sunakawa: Financial Interests, Personal, Speaker, Consultant, Advisor: Ono Pharmaceutical Co. Ltd., Merck Biopharma Co., Ltd, Guardant Health Japan Co; Financial Interests, Personal, Other, Honoraria: Bristol Myers Squibb Co. Ltd, Bayer Yakuhin Ltd., Eli Lilly Japan K.K., MSD K.K, Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd, Takeda Pharmaceutical Co. Ltd., Merck Biopharma Co., Ltd, Guardant Health Japan Co., Sysmex Co., Taiho Pharmaceutical Co. Ltd; Financial Interests, Personal, Research Funding: Chugai Pharmaceutical Co. Ltd, Takeda Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Sanofi, Taiho Pharmaceutical Co. Ltd., Ohtsuka Pharmaceutical Co. A. Takashima: Financial Interests, Personal, Research Grant: Takeda, Ono Pharmaceutical, Merck Sharp & Dohme, Bristol Myers Squibb, Isofol Medical AB, Hutchison Medipharma, Incyte Corporation, Pfizer Inc, Daiichi Sankyo; Financial Interests, Personal, Other, Personal fees: Eli Lilly, Taiho Pharmaceutical, Ono Pharmaceutical, Chugai Pharmaceutical, Takeda, Merck Serono, Merck Sharp & Dohme. K. Yamazaki: Financial Interests, Personal, Other, Personal fees and honoraria: Chugai Pharmaceutical, Daiichi Sankyo, Yakult Honsha, Takeda, Bayer, Merck Serono, Taiho Pharmaceutical, Eli Lilly, Sanofi, Ono Pharmaceutical, Merck Sharp & Dohme, Bristol Myers Squibb. H. Kawakami: Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Taiho Pharmaceutical Co. Ltd.; Financial Interests, Personal, Other, Honoraria: Bristol Myers Squibb Co. Ltd., AstraZeneca K.K, Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd, Daiichi Sankyo Co. Ltd.; Financial Interests, Personal, Other, Lecture fees: Bristol Myers Squibb Co. Ltd, Eli Lilly Japan K.K., MSD K.K, Ono Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Chugai Pharmaceutical Co. Ltd, Takeda Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd.; Financial Interests, Personal, Research Funding: Bristol Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Eisai Co. Ltd. T. Nishina: Financial Interests, Personal, Other, Honoraria: Ono Pharmaceuticals, Taiho Pharmaceuticals, Takeda Pharmaceuticals, Chugai Pharmaceuticals, Daiichi Sankyo. Y. Komatsu: Financial Interests, Personal, Research Grant: Takeda, Chugai, Nihonkayaku, Nipro, Taiho Pharmaceutical, Ono Pharmaceutical, Nippon Zoki, Shionogi, EPS, IQVIA, Astellas, Eisai, Merck Sharp & Dohme, Yakult, Daiichi Sankyo, Eli Lilly, Sanofi, Bristol Myers Squibb; Financial Interests, Personal, Research Funding: Takeda, Chugai, Nihonkayaku, Nipro; Financial Interests, Personal, Speaker’s Bureau, Speakers bureau membership: Chugai, Nihonkayaku; Financial Interests, Personal, Other, Personal fees: Chugai, Nihonkayaku, Taiho Pharmaceutical, Ono Pharmaceutical, Yakult, Daiichi Sankyo, Eli Lilly, Bayer, Pfizer, Bristol Myers Squibb, Asahi Kasei. T. Esaki: Financial Interests, Personal, Research Grant: MSD, Novartis, Dainippon Sumitomo, Ono, Daiichi Sankyo, Astellas, Astellas Amgen Biopharma, Parexel, Chugai, Quintiles, Syneos Health, PfIzer; Financial Interests, Personal, Other, Honoraria: MSD, Tahio, Ono, Daiichi Sankyo, Lilly, Chugai, Sanofi. C. Eng: Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, Bayer, Ca Institute of Regenerative Medicine, Elevation, GE, GSK, IGM, Merck, Natera, Pfizer, Taiho, Seagen ; Financial Interests, Institutional, Research Funding: Merck, Hutchi-Med, Pfizer, Janssen, Gritstone. N.A. Dasari: Financial Interests, Institutional, Research Grant: Hutchmed, Guardant Health, Natera Inc, Eisai, Crinetics, AAA / Novartis; Financial Interests, Personal, Advisory Board: Hutchmed, Crinetics, Voluntis, AAA / Novartis, Personalis Inc. Z. Yu: Financial Interests, Personal, Full or part-time Employment: Takeda. L. Chen: Financial Interests, Personal, Full or part-time Employment: Takeda. T. Yang: Financial Interests, Personal, Full or part-time Employment: HUTCHMED. W. Schelman: Financial Interests, Personal, Full or part-time Employment: HUTCHMED. T. Satoh: Financial Interests, Personal, Other, Honoraria: Daiichi Sankyo, Ono Pharmaceutical, Bristol Myers Squibb, Elli Lilly; Financial Interests, Personal, Research Funding: Daiichi Sankyo, Ono Pharmaceutical, Bristol Myers Squibb, MSD, Hutch Med, Taiho Pharmaceutical, Shionogi Pharmaceutical, Elli Lilly.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract